TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG) is a life sciences company advancing precision medicine through innovative whole-transcriptome profiling technology The company, Fundación Instituto Valenciano de Oncología (IVO) in Valencia, Spain, together with its partners Fundación Pública Andaluza Progreso y Salud (FPS) and Centro de Investigación Biomédica en Red (CIBER), has developed a laboratory The test (LDT) (MPD test) is used to assess breast cancer recurrence based on the use of HTG EdgeSeq™ technology.
This innovative test for HR+/HER2- early breast cancer patients was developed by IVO and its partners to identify patients at high risk of distant metastasis or recurrence who may benefit from adjuvant chemotherapy. rice field. IVO is one of the top 50 cancer hospitals in the world. FPS is a public institution primarily dedicated to research and information technology. CIBER is a public research consortium aimed at advancing research in biomedical and health sciences.
This highly talented and experienced team of researchers has partnered to develop and validate MPD tests using HTG EdgeSeq technology. This, coupled with the sensitivity and dynamic range of next-generation sequencing, typically requires only one 5-μm-thin His FFPE tissue biopsy section. (NGS)-based detection that produces results in as little as 3 days.
HTG Senior Vice President and Chief Commercial Officer Byron Lawson said: “The MPD test is a great example of how HTG EdgeSeq technology can be used not only for molecular profiling and analysis, but also as a predictive tool to advance precision medicine.”
Dr. José Antonio López-Guerrero, Director of IVO’s Molecular Biology Laboratory, said: “When the results of two different genomic assays are inconsistent, it can have significant clinical implications for patients, for example in determining whether a patient chooses to undergo chemotherapy. Leveraged, the MPD test reduces time to results, reduces potential risk of bias, and improves overall risk profile using only small samples from tissue biopsies We see it as a cost-effective option for
The MPD test is available as an LDT offered by IVO and its partners.
About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of whole-transcriptome profiling to drive translational research, novel therapeutics, and clinical diagnostics across disease areas. increase.
Built on more than a decade of pioneering innovation and partnerships with biopharmaceutical leaders and leading academic institutions, HTG’s proprietary RNA platform technology makes the development of life science tools and diagnostics more effective and efficient. , designed to unlock a differentiated and disruptive approach to transformation. Drug discovery.
For more information, please visit www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding: The MPD test demonstrates how HTG EdgeSeq technology can be used for molecular profiling and analysis, and as a predictive tool to advance precision medicine. The MPD test is cost effective to reduce time to results, reduce potential risk of bias, and improve overall risk profile using only small samples from tissue biopsies. belief that it is a viable option; features, applications and design advantages of using HTG’s EdgeSeq technology; Words such as “may”, “designed to”, “believe”, “typically”, “may” and similar expressions are intended to identify forward-looking statements. For our purposes, not all forward-looking statements contain these specific words. These forward-looking statements are based on management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or prove to be incorrect. I’m here. Actual results and timing of events are subject to various risks and uncertainties, including but not limited to the risk that the HTG EdgeSeq technology or our RNA platform technology may not perform as expected. They may differ materially from those anticipated in forward-looking statements. Or provide the benefits we expect. Uncertainty regarding the effectiveness of using the HTG EdgeSeq technology as a predictive tool. Risks associated with relying on third parties to use and validate our technology. Risks associated with our ability to develop and commercialize products containing HTG EdgeSeq technology. Our ability to manufacture products that meet demand. competition in our industry; availability of additional capital and credit; and our ability to attract and retain qualified personnel. and product liability claims. These and other factors have been disclosed to the U.S. Securities and Exchange Commission (SEC), including under the heading “Risk Factors,” in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed June 30, 2022. are detailed in the submission documents. Jointly with the SEC on August 12, 2022. the date they were created.
HTG Investor Contact:
Ashley Robinson
Life Science Advisor
Phone: (617) 430-7577
Email: arr@lifesciaadvisors.com
